JGC
APLT

J. Goldman & Co’s Applied Therapeutics APLT Stock Holding History

J. Goldman & Co’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,000
Closed -$102K – 453
2024
Q3 		$102K Buy
+12,000
New +$70.7K ﹤0.01% 428

Other funds holding APLT

VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

J. Goldman & Co's APLT Position: Q2 2024 in Review

J. Goldman & Co sold out of Applied Therapeutics (APLT) in Q2 2024, closing a stake of 146,392 shares — an estimated $693K sold.

J. Goldman & Co first reported a position in APLT in Q1 2024 and held it in 1 quarter. The position peaked at $995K in Q1 2024. 94 funds tracked by Wall St. Rank hold APLT as of Q2 2024.

  • J. Goldman & Co reported no remaining Applied Therapeutics position as of Q2 2024 after selling out during the quarter.
  • J. Goldman & Co sold 146,392 Applied Therapeutics shares in Q2 2024, an estimated $693K.
  • J. Goldman & Co first reported a position in Applied Therapeutics in Q1 2024 and held it in 1 quarter.
  • J. Goldman & Co's Applied Therapeutics position peaked at $995K in Q1 2024.
  • 94 funds tracked by Wall St. Rank held Applied Therapeutics as of Q2 2024.

Based on J. Goldman & Co's 13F filing for Q2 2024, filed 14 Aug 2024.